SAT-LB074 Efficacy and Safety of Once-weekly Somapacitan in Adult Growth Hormone Deficiency (AGHD) Confirmed in a 53‑week Real 1 Trial Extension

The 34-week double-blind placebo-controlled main phase of REAL 1 (NCT02229851) has been previously presented (Johannsson G et al. 2018.). Now we report the open-label extension of this trial evaluating efficacy and safety of somapacitan in male/female patients aged 23-79 years with AGHD, for an addi...

Descripción completa

Detalles Bibliográficos
Autores principales: Johannsson, Gudmundur, Gordon, Murray, Højby Rasmussen, Michael, Holme Håkonsson, Ida, Sværke, Claus, Tahara, Shigeyuki, Takano, Koji, Biller, Beverly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Neuroendocrinology and Pituitary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552458/
http://dx.doi.org/10.1210/js.2019-SAT-LB074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552458/
http://dx.doi.org/10.1210/js.2019-SAT-LB074

Ejemplares similares